Background
Phase 3, open-label, randomized controlled trial (COMPLEMENT 1). N=447 patients with treatment-naive CLL not eligible for fludarabine-based therapy (age ≥65, impaired organ function, or CIRS >6). Chlorambucil is a traditional oral alkylating agent; ofatumumab is a fully human anti-CD20 IgG1 monoclonal antibody targeting a distinct CD20 epitope. Randomized 1:1.
Interventions and follow up
Arm A: Ofatumumab 300 mg IV cycle 1 day 1, then 1000 mg IV day 8 cycle 1 and day 1 cycles 2–12 + chlorambucil 10 mg/m²/day PO days 1–7 q28d × 12 cycles
Arm B: Chlorambucil 10 mg/m²/day PO days 1–7 q28d × 12 cycles (monotherapy)
Primary endpoint: Progression-free survival (PFS)
Median follow up: 28.9 months
Arm B: Chlorambucil 10 mg/m²/day PO days 1–7 q28d × 12 cycles (monotherapy)
Primary endpoint: Progression-free survival (PFS)
Median follow up: 28.9 months
Results
Median PFS: 22.4 vs 13.1 months (ofatumumab+Clb vs Clb), HR 0.57 (95% CI 0.45–0.72), P<.001
ORR: 82% vs 69% (P<.001)
CR: 12% vs 1%
OS: HR 0.78, P=.14 — not significant
ORR: 82% vs 69% (P<.001)
CR: 12% vs 1%
OS: HR 0.78, P=.14 — not significant
Adverse events
Infusion reactions: Any grade 67% (ofatumumab arm), grade ≥3 3%.
Hematologic: Grade ≥3 neutropenia 26% (ofatumumab+Clb) vs 14% (Clb).
Infections: Grade ≥3 infections 15% vs 14%.
Other: Nausea and fatigue more common with chlorambucil.
Hematologic: Grade ≥3 neutropenia 26% (ofatumumab+Clb) vs 14% (Clb).
Infections: Grade ≥3 infections 15% vs 14%.
Other: Nausea and fatigue more common with chlorambucil.
Conclusions
Ofatumumab + chlorambucil significantly improved PFS and ORR compared with chlorambucil alone in fit-for-chlorambucil treatment-naive CLL. No OS benefit was demonstrated. This established anti-CD20 antibody addition to chlorambucil as superior to chlorambucil monotherapy in elderly/unfit CLL.
Key Limitations
The chlorambucil monotherapy comparator is a weak benchmark; obinutuzumab+chlorambucil (CLL11) showed superior outcomes over rituximab+Clb, limiting the relevance of the ofatumumab+Clb regimen. No OS benefit. The trial included no rituximab+Clb arm, making cross-trial comparison with CLL11 indirect. In contemporary practice, both ofatumumab and chemoimmunotherapy regimens have been largely replaced by BCL-2i- and BTKi-based regimens.
Clinical Context
Ofatumumab + chlorambucil was FDA-approved in 2014 for previously untreated CLL patients deemed ineligible for fludarabine therapy. The regimen was subsequently largely supplanted by obinutuzumab + chlorambucil (CLL11, CLL14) and then by fixed-duration venetoclax-obinutuzumab (CLL14) and BTKi-based regimens. Ofatumumab has since been withdrawn from most CLL markets. Historical importance: confirmed anti-CD20 benefit in unfit CLL. ESMO-MCBS: not currently assigned.